Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 6/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2142804 | 0.91 | CYP2C8 (1.00) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2141750 | 0.84 | CYP2C8 (0.88) | CYP2C8CYP3A4KCNH2NR1I2ABL1 | |
| SCHEMBL2143177 | 0.84 | CYP2C8 (0.87) | CYP2C8CYP3A4KCNH2NR1I2ABL1 | |
| SCHEMBL2141388 | 0.83 | CYP2C8 (0.86) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2141972 | 0.82 | CYP2C8 (1.00) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2141169 | 0.81 | CYP2C8 (0.83) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2143486 | 0.81 | CYP2C8 (0.83) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL12293914 | 0.81 | CYP2C8 (0.70) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL9912760 | 0.81 | CYP2C8 (0.82) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL12293750 | 0.81 | CYP2C8 (0.85) | CYP2C8CYP3A4KCNH2NR1I2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048887-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-01 | — | — | US | claimed |